---
title: "Understanding the Market | ASCLETIS-B rises over 5% as ASC30 demonstrates superior efficacy and safety data; the company has many catalysts in the second half of the year"
description: "ASCLETIS-B's stock price rose by more than 5%, with an increase of 5.02% as of the time of publication, reported at HKD 10.88, with a trading volume of HKD 92.5898 million. The company reported the cl"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257665913.md"
published_at: "2025-09-17T07:05:04.000Z"
---

# Understanding the Market | ASCLETIS-B rises over 5% as ASC30 demonstrates superior efficacy and safety data; the company has many catalysts in the second half of the year

> ASCLETIS-B's stock price rose by more than 5%, with an increase of 5.02% as of the time of publication, reported at HKD 10.88, with a trading volume of HKD 92.5898 million. The company reported the clinical research results of ASC30 at the upcoming European Association for the Study of Diabetes annual meeting, showing superior performance in weight loss and safety. Soochow Securities pointed out that the company has several important clinical data set to be disclosed in the second half of the year and is expected to submit multiple new pipeline INDs to the FDA

According to Zhitong Finance APP, ASCLETIS-B (01672) rose over 5%, with a current increase of 5.02%, priced at HKD 10.88, and a trading volume of HKD 92.5898 million.

In terms of news, ASCLETIS announced this morning that it will report the results of its ASC30 oral small molecule GLP-1R agonist 28-day multiple dose escalation study at the 61st Annual Meeting of the European Association for the Study of Diabetes to be held in Vienna, Austria on September 16, 2025. The ASC30 once-daily oral tablet showed a relative baseline average weight loss of up to 6.5% after 28 days of treatment, adjusted for placebo; the superior efficacy of ASC30 tablets is attributed to its higher oral drug exposure; ASC30 demonstrated good safety and tolerability, with only mild to moderate gastrointestinal (GI) adverse events (AE) reported. Due to the weekly titration strategy of 2 mg to 5 mg used in the multiple dose escalation (MAD) cohort 1, no vomiting occurred in this cohort.

Soochow Securities recently pointed out that the company has many catalysts in the second half of the year, with several important clinical data sets about to be disclosed: based on clinical trial progress and company announcements, the firm expects to read out the top-line data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I in Q4 2025, and the top-line data for ASC30 subcutaneous injection Phase II in Q1 2026. At the same time, the company expects to submit 2-3 new pipeline INDs to the FDA in the next 6-9 months, including a dual-target peptide weight loss pipeline

### Related Stocks

- [01672.HK - ASCLETIS-B](https://longbridge.com/en/quote/01672.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Ascletis Pharma Boosts Share Buyback Plan to HK$500 Million | Ascletis Pharma Boosts Share Buyback Plan to HK$500 Million | [Link](https://longbridge.com/en/news/269948463.md) |
| Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials | Ascletis Pharma Inc. plans to raise approximately HK$835 million through a share placement of 69,256,000 new shares at H | [Link](https://longbridge.com/en/news/274573426.md) |
| How Does High-Altitude Living Lower Diabetes Risk? | Researchers at the Gladstone Institutes have explored how high-altitude living may lower diabetes risk. Their study on h | [Link](https://longbridge.com/en/news/276481731.md) |
| GIC Private Limited initiated a stake in Ascletis Pharmaby 64,128,000 shares at a price of HKD 12.18 per share | GIC Private Limited has acquired a stake in Ascletis Pharmaby purchasing 64,128,000 shares at HKD 12.18 each, totaling a | [Link](https://longbridge.com/en/news/275105288.md) |
| Ascletis Pharma Wins FDA IND Clearance for Phase II Diabetes Study | Ascletis Pharma Inc. has received FDA IND clearance for a 13-week Phase II clinical study of its oral GLP-1 candidate, A | [Link](https://longbridge.com/en/news/271437602.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.